Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Dupixent Legal and Medical Information About T-cell Lymphoma

October 8, 2025 By Law Offices of Thomas J. Lamb, P.A.

In this brief article, we present important Dupixent legal and medical information about T-cell lymphoma, which appears to be a Dupixent-related side effect.

We start with some of the allegations contained in the lawsuits being filed against the pharmaceutical companies Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC, based on various allegations of legal liability concerning the potential increased risk of T-cell lymphoma:

  1. Defendants Regeneron and Sanofi knew or should have known of the potential of Dupixent to exacerbate or accelerate pre-existing T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), or increase susceptibility to its development.
  2. Defendants failed to adequately test Dupixent to investigate the risks, including the potential of exacerbating pre-existing T-cell lymphoma or increasing susceptibility to its development.
  3. Defendants failed to warn physicians and patients that Dupixent should not be prescribed or administered to patients with confirmed or suspected T-cell lymphoma, including CTCL and PTCL.

Next, we provide some medical information about T-cell lymphoma:

  • There are several types of T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
  • CTCL is a T-cell lymphoma that begins in the skin. Mycosis fungoides and Sézary syndrome are the two most common subtypes of CTCL.
  • PTCL refers to systemic T-cell lymphomas that are found in the lymph nodes, other organs, and the blood. Also, some types involve the skin.
  • T-cell lymphomas, both CTCL and PTCL, are a subtype of non-Hodgkin lymphoma (NHL).

We are currently investigating possible Dupixent legal compensation cases for patients who were diagnosed with one of more types of T-cell lymphona some time after they started using Dupixent.

For those patients, we encourage you to submit a Drug Injury Case Evaluation Form online — it is free, confidential, and there is no obligation. You will get a reply from us no later than the next business day. Or call attorney Tom Lamb at 910-256-2971 to discuss their potential Dupixent legal case.


Dupixent

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: cutaneous T-cell lymphoma (CTCL), Dupixent, mycosis fungoides, peripheral T-cell lymphoma (PTCL), Sézary syndrome, T-cell lymphoma

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call 910-256-2971 to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

910-256-2971

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.